FGF23 and mesenchymal cell neoplasm: Patients with TIO typically exhibit hypophosphataemia, hyperphosphaturia, and elevated FGF23 levels, prompting clinicians to incorporate bone imaging modalities to identify the mesenchymal tumour responsible for these laboratory abnormalities.